Top Stock Reports For Berkshire Hathaway, Colgate & CME Group
Zacks Investment Research | Jun 04, 2018 11:42PM ET
Tuesday, June 5, 2018
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway (BRK.B), Colgate (CL) and CME Group (CME). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
Buy-ranked Berkshire Hathaway’s shares have gained +14.9% in the last year, outperforming the Zacks Property and Casualty Insurance industry which increased +11.3% during the same period. The Zacks analyst thinks Berkshire’s inorganic growth story remains impressive with strategic acquisitions. A strong cash position allows it to make earnings-accretive bolt-on acquisitions.
Demand for utilities is expected to rise in the future and drive earnings growth. Continued insurance business growth also fuels increase in float. A sturdy capital level further adds an impetus to the company. The insurance business generates maximum return on equity but its exposure to catastrophe loss remains a concern.
Huge capital expenses due to railroad operations have also emerged as headwinds. Capital expenditures are estimated at $10 billion in 2018. Nonetheless, the stock has witnessed its 2018 and 2019 estimates move up in the last 30 days.
(You can ).
Shares of Colgate have lost -10% over the last three months, underperforming the Zacks Consumer Staples sector, which has declined -8.1% over the same period. Colgate has been popular with investors for its meet or beat earnings track record.
Continuing with this trend, the company delivered an earnings beat in first-quarter 2018, after three consecutive quarters of in line earnings. Results continue to be driven by sales growth and significant market share gains. Going forward, the company remains on track with brand building and productivity maximization initiatives. Consequently, it provided a robust outlook for 2018.
Further, the company is encouraged by the progress on Global Growth and Efficiency Program along with additional savings anticipated from the recent expansion of the program. However, the company’s margins continue to be strained by higher raw material and packaging costs. Moreover, Colgate expects the backdrop to remain challenging in 2018 due to uncertain global markets and slowing category growth worldwide.
Get The News You Want
(You can ).
CME Group’s shares have outperformed the Zacks Securities and Exchanges industry in the last six months, gaining +11.5% vs. +6%. The Zacks analyst thinks the company remains well-positioned for growth on a strong market position with diverse derivative product lines.
Efforts to expand and cross sell its core exchange-traded business via new product initiatives and global reach also support growth. It intends to exit its credit default swap clearing business by mid-2018 and focus on over-the-counter clearing services on interest rate swaps as well as foreign exchange. This will free up $650 million as clearing member capital.
Also, the buyout of Nex Group will help CME generate $200 million in run-rate cost synergies annually by the end of 2021. However, exposure to interest rate volatility and limited credit availability might hamper liquidity.
(You can ).
Other noteworthy reports we are featuring today include Tesla (NASDAQ:TSLA), PPL Corporation (NYSE:PPL) and lululemon (LULU).
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly
Today's Must Read/h6
Featured Reports/h6
Per the Zacks analyst, while Emergent's follow-on contract with the CDC and deals with the BARDA for BioThrax and NuThrax look good, the company is highly dependent on BioThrax for growth.
Sales of Puma's marketed drug, Nerlynx for breast cancer in the United States have improved steadily since launch in July 2017.
Per the Zacks analyst, the company invests in technology and automation to reduce costs and meet rising production rates on many programs.
Per the Zacks analyst, Altice remains on track to build a FTTH network to capitalize on associated revenue-growth opportunities, although continued high programming costs remain perennial concerns.
Per the Zacks analyst, EnerSys' steady revenue growth and operational efficiencies are being dampened by a steep rise in commodity costs which is hurting the bottom line.
Per the Zacks analyst, American Public Education will continue to improve enrollment trends by strengthening its brand and adding new programs.
Per the Zacks analyst, Lululemon's top-line is gaining from its 2020 strategy.
Per the Zacks analyst, while Emergent's follow-on contract with the CDC and deals with the BARDA for BioThrax and NuThrax look good, the company is highly dependent on BioThrax for growth.
Sales of Puma's marketed drug, Nerlynx for breast cancer in the United States have improved steadily since launch in July 2017.
Per the Zacks analyst, the company invests in technology and automation to reduce costs and meet rising production rates on many programs.
Per the Zacks analyst, Altice remains on track to build a FTTH network to capitalize on associated revenue-growth opportunities, although continued high programming costs remain perennial concerns.
Per the Zacks analyst, EnerSys' steady revenue growth and operational efficiencies are being dampened by a steep rise in commodity costs which is hurting the bottom line.
Per the Zacks analyst, American Public Education will continue to improve enrollment trends by strengthening its brand and adding new programs.
Per the Zacks analyst, Lululemon's top-line is gaining from its 2020 strategy.
New Upgrades/h6
Per the Zacks analyst, rise in order flow and total bookings with continued growth in Asia Pacific service providers as well as global webscale customers will continue to boost Ciena's top-line.
Per the Zacks analyst, rise in deliveries of powerpacks will help Tesla's Energy & Storage unit to drive sales and also attain its aim to triple energy storage deployments in 2018.
The Zacks analyst is bullish on ResMed's receipt of French reimbursement nod for mandibular repositioning devices. ResMed expects South Korea to start reimbursing treatment for sleep apnea soon.
Per the Zacks analyst, rise in order flow and total bookings with continued growth in Asia Pacific service providers as well as global webscale customers will continue to boost Ciena's top-line.
Per the Zacks analyst, rise in deliveries of powerpacks will help Tesla's Energy & Storage unit to drive sales and also attain its aim to triple energy storage deployments in 2018.
The Zacks analyst is bullish on ResMed's receipt of French reimbursement nod for mandibular repositioning devices. ResMed expects South Korea to start reimbursing treatment for sleep apnea soon.
New Downgrades/h6
Per the Zacks analyst, elevated costs of certain key raw materials including alumina will weigh on Century Aluminum's margins. High prices for power at its Mt. Holly smelter is another concern.
Per the Zacks analyst, Broadcom's leveraged balance sheet and customer concentration continue to be headwinds. Also, stiff competition, integration risks and pricing pressure adds to its woes.
The Zacks analyst believes PPL Corporation's prospects could be adversely impacted by its high debt levels amid rising interest rates and stringent regulation of emissions.
Per the Zacks analyst, elevated costs of certain key raw materials including alumina will weigh on Century Aluminum's margins. High prices for power at its Mt. Holly smelter is another concern.
Per the Zacks analyst, Broadcom's leveraged balance sheet and customer concentration continue to be headwinds. Also, stiff competition, integration risks and pricing pressure adds to its woes.
The Zacks analyst believes PPL Corporation's prospects could be adversely impacted by its high debt levels amid rising interest rates and stringent regulation of emissions.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.